These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17689623)

  • 41. Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.
    Parasrampuria DA; Vaughan S; Ariyawansa J; Swinnen A; Natarajan J; Rasschaert F; Massarella J; Fonseca S
    Contraception; 2020 Apr; 101(4):276-282. PubMed ID: 31935382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
    White T; Jain JK; Stanczyk FZ
    Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study.
    Weisberg F; Bouchard C; Moreau M; Audet MC; Mawdsley S; Dattani D; Dinniwell J; Horbay GL;
    J Obstet Gynaecol Can; 2005 Apr; 27(4):350-9. PubMed ID: 15937609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The contraceptive patch. Latest developments.
    Courtney K
    AWHONN Lifelines; 2006; 10(3):250-4. PubMed ID: 16792714
    [No Abstract]   [Full Text] [Related]  

  • 45. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.
    Raymond EG; Burke AE; Espey E
    Obstet Gynecol; 2012 May; 119(5):1039-44. PubMed ID: 22525916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New contraceptive methods.
    Plourd DM; Rayburn WF
    J Reprod Med; 2003 Sep; 48(9):665-71. PubMed ID: 14562628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of a transdermal contraceptive system.
    Smallwood GH; Meador ML; Lenihan JP; Shangold GA; Fisher AC; Creasy GW;
    Obstet Gynecol; 2001 Nov; 98(5 Pt 1):799-805. PubMed ID: 11704172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Less estrogen in new oral contraceptive.
    Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
    [No Abstract]   [Full Text] [Related]  

  • 49. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Innovations in contraception: a review.
    Zurawin RK; Ayensu-Coker L
    Clin Obstet Gynecol; 2007 Jun; 50(2):425-39. PubMed ID: 17513928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmacokinetics of 12-week continuous contraceptive patch use.
    Lavelanet AF; Rybin D; White KO
    Contraception; 2017 Jun; 95(6):578-585. PubMed ID: 28285154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic overview of Ortho Evra/Evra.
    Abrams LS; Skee D; Natarajan J; Wong FA
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of estrogen-withdrawal headache with extended transdermal contraception.
    LaGuardia KD; Fisher AC; Bainbridge JD; LoCoco JM; Friedman AJ
    Fertil Steril; 2005 Jun; 83(6):1875-7. PubMed ID: 15950671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP; Mathias A
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment satisfaction with a transdermal contraceptive patch or oral contraceptives.
    Wan GJ; Barnowski CE; Ambegaonkar BM; Bolge SC; McDonnell DD
    Contraception; 2007 Apr; 75(4):281-4. PubMed ID: 17362706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch.
    Graziottin A
    Treat Endocrinol; 2006; 5(6):359-65. PubMed ID: 17107221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined hormonal contraception.
    Calderoni ME; Coupey SM
    Adolesc Med Clin; 2005 Oct; 16(3):517-37. PubMed ID: 16183537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical use of norgestrel-ethinyl oestradiol as a contraceptive.
    Tyler ET; Matsner EM; Gotlib MH; Levin M; Daniels T; Shimabukuro B; Dolman H; Elliot J
    J Reprod Fertil Suppl; 1968 Dec; 5():Suppl 5:109-16. PubMed ID: 5288229
    [No Abstract]   [Full Text] [Related]  

  • 59. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra).
    Zieman M
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S1-2. PubMed ID: 11849629
    [No Abstract]   [Full Text] [Related]  

  • 60. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.
    Archer DF; Cullins V; Creasy GW; Fisher AC
    Contraception; 2004 Mar; 69(3):189-95. PubMed ID: 14969665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.